Leadership Roles Appointed To Fosamax Lawyers By Judge

Leadership roles were given to several Fosamax lawyers by US District Judge Garret E. Brown, Jr. in the recently formed multidistrict litigation (MDL) on Fosamax femur fracture lawsuits. The US Judicial Panel On Multidistrict Litigation had ordered the consolidation of all federal Fosamax femur fracture lawsuits under Brown last May. It should be known by those taking Fosamax that Not taking Fosamax correctly could damage your lawsuit against Merck.

The appointed attorneys will perform certain actions during the coordinated litigation that will benefit all plaintiffs who have filed a lawsuit over a fractured femur from prolonged Fosamax intake. Fosamax (alendronate sodium) which belongs to a group of drug called Bisphosphonate is a popular osteoporosis medication manufactured by Merck & Co. since 1995. Although it was designed to strengthen the bones, recent studies have suggested that long-term use of Fosamax and other Bisphosphonates might lead to severe side effects such as femur fractures, osteonecrosis, musculoskeletal pain and esophageal cancer.

Those undergoing Fosamax medication are warned to seek immediate medical attention if they experience groin pain, which may occur several weeks before a complete fracture while on Fosamax, as prompted by studies. As alleged by all lawsuits involved in the MDL, side effects of Fosamax increase the risk of atypical femur fractures, which can occur with little or no trauma at all. According to the plaintiffs, Merck allegedly failed to properly research the medication or adequately warn consumers.

A growing number of Fosamax lawyers throughout the United States have been reviewing and filing lawsuits on behalf of individuals who suffered a sudden femur fracture while taking the medication since the Food and Drug Administration (FDA) required new warnings about the risk of Fosamax thigh bone fractures in October 2010. There were about 36 Fosamax fracture lawsuits pending in federal district courts throughout the United States at the time the MDL was formed. Since then a larger number of cases have been filed in the state court in New Jersey and other states throughout the United States while some 24 additional cases since then have been transferred to the MDL.

The MDL on Fosamax lawsuits over jaw problems known as osteonecrosis of the jaw will remain centralized as part of a different MDL in the U.S. District Court for the Southern District of New York, before U.S. District Judge John F. Keenan, thus it will not be affected by this MDL. More than 900 Fosamax jaw lawsuits were consolidated in New York, as part of an MDL that was established in August 2006. It was determined that the evidence of general causation leading to femur fractures would likely differ substantially from cases dealing with jaw bone damage thus the Fosamax fracture lawsuits were excluded from this MDL.

Be Sociable, Share!

Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *

CommentLuv badge